2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transfusion, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4561 First results from commitmentt-tal: A real-world (RW) study of talquetamab monotherapy in late-line relapsed/refractory multiple myeloma (RRMM) across North America, Europe, Latin America, and Asia

Johannes Waldschmidt, MD, Kazuhito Suzuki, MD, PhD2, Jian Li, MD3, Gloria Graf, PhD, MPH4, Naama Kipperman, MPH5, Wing Chow, PharmD, MS6, Sikander Ailawadhi, MD7, Rahul Banerjee, MD8, Guido Lancman, MD, MSc9, Joaquin Martinez-Lopez Sr, MD, PhD10, Jill Zitzewitz, PhD11, Katarina Uttervall, MD, PhD12, K. Martin Kortüm, MD13, Debbie Goldschmidt, PhD14, Todor Totev, MBA15, Wilson Da Costa, Jr., MD, PhD16, Dana Christensen, MPH17, Ming-Hui Tai18, Shuchita Kaila, PhD19, Eric Aeby, PhD20, Guntug Gungor, MD21, Tatsunori Jinnai22, Chika Sakai23, Xiaohong Wang, MSc24, Haoyan CAI, MD25, Rocío Monserrat Rojas Sotelo, MD26, Lori Parisi27, Mark Wildgust, PhD28, Bingcao Wu, PhD29, Mariana Fernandez, MD30, Vania Hungria, MD, PhD31
1 Universitätsklinikum Würzburg, Würzburg, Germany
2 The Jikei University School of Medicine, Tokyo, Japan
3 Peking Union Medical College Hospital (PUMCH), Beijing, China
4 Johnson & Johnson, Raritan, New Jersey, United States
5 Johnson & Johnson, Raritan, New Jersey, United States
6 Johnson & Johnson, Raritan, New Jersey, United States
7 Mayo Clinic Florida, Jacksonville, Florida, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 Princess Margaret Cancer Centre, Toronto, Canada
10 Hospital Universitario 12 de Octubre, Madrid, Spain
11 UMass Chan Medical School, Worcester, Massachusetts, United States
12 Karolinska University Hospital, Stockholm, Sweden
13 Universitätsklinikum Würzburg, Würzburg, Germany
14 Analysis Group, New York, New York, United States
15 Analysis Group, Boston, Massachusetts, United States
16 Analysis Group, Boston, Massachusetts, United States
17 Analysis Group, New York, New York, United States
18 Johnson & Johnson, Horsham, Pennsylvania, United States
19 Johnson & Johnson, Horsham, Pennsylvania, United States
20 Johnson & Johnson, Zug, Switzerland
21 Johnson & Johnson, Breda, Netherlands
22 Johnson & Johnson, Tokyo, Japan
23 Johnson & Johnson, Tokyo, Japan
24 Johnson & Johnson, Shanghai, China
25 Johnson & Johnson, Beijing, China
26 Johnson & Johnson, Mexico City, Mexico
27 Johnson & Johnson, Raritan, New Jersey, United States
28 Johnson & Johnson, Raritan, New Jersey, United States
29 Johnson & Johnson, Raritan, New Jersey, United States
30 Johnson & Johnson, Madrid, Spain
31 Clinica São Germano, São Paulo, Brazil

Background: Talquetamab (Tal) is a first-in-class GPRC5D-targeting bispecific antibody first approved as monotherapy for the treatment of triple-class-exposed RRMM. Evidence from real-world cohorts to date supports the efficacy and safety profile of Tal, with outcomes comparable to the pivotal MonumenTAL-1 trial in a broad RRMM population. Pooling data across a large global cohort provides a novel opportunity to characterize treatment strategies across diverse real-world settings and evaluate whether outcomes remain consistent across clinically challenging patient profiles.  

Aims: CoMMitmenTT is a global, chart-review-based platform study pooling data from multiple sources to evaluate real-world treatment patterns and outcomes among patients receiving teclistamab or talquetamab commercially or through expanded-access programs. In this first report of talquetamab patients outside of clinical trials, we present initial pooled results from four cohorts in the United States (US) and Europe/Middle East/Africa (EMEA), along with subgroup analyses of patients with renal impairment, high-risk cytogenetic abnormalities (HRCA), and elderly patients (≥75 years). Data collection is ongoing in Brazil, Germany, Japan, and China; updated results including these cohorts will be presented at the time of conference presentation. 

Methods: We pooled individual patient-level data from four retrospective company-sponsored chart reviews in the US (data collection April 2025 to December 2025) and EMEA (multi-country cohort December 2023 to August 2025; Spain cohort September 2024 to May 2025; Germany cohort April 2026 to June 2026). Eligibility criteria for inclusion in CoMMitmenTT included confirmed RRMM diagnosis, initiation of talquetamab monotherapy outside of a clinical trial, adult age (≥18 years), and ≥1 month follow-up. Patients who received talquetamab as bridging therapy were excluded. Renal impairment was defined as recorded and collected within each cohort. HRCA was defined as presence of at least one of the following: del(17p), t(4;14), t(14;16), amp(1q), del(1p); in the US cohort, del(1p) was not collected and hence not included in HRCA classification.  

Results: A total of 541 patients were eligible for study inclusion (median age 68 years [range 24-86], median prior lines of therapy (PL) 4 [range 1.0-16.0], 93.2% triple-class exposed (TCE, n=504), 59.3% penta-class exposed (PCE, n=321), 75.4% triple-class refractory (TCR, n=408), 41.6% (n=225) prior BCMA exposure; 16.1% (n=87) with renal impairment, 27.0% (n=146) HRCA, 21.1% (n=114) aged ≥75 years). Median follow-up was 9.5 months (9.9 in the US cohort, 11.2 in the EMEA multi-country cohort, 12.0 in the Spanish cohort, and 3.7 in the German cohort where data collection is ongoing). Subgroup patient characteristics were comparable to the overall cohort (renal impairment: median age 71, median PL 4, 88.5% TCE, 60.9% PCE, 72.4% TCR, 44.8% prior BCMA. HRCA: median age 68, median PL 4, 89.7% TCE, 56.8% PCE, 70.5% TCR, 41.8% prior BCMA. elderly: median age 78, median PL 4, 92.1% TCE, 56.1% PCE, 64.9% TCR, 46.5% prior BCMA). 

ORR in the overall cohort was 83.1% (60.6% ≥VGPR); 12-mo PFS and OS estimates were 54.7% and 74.7%. Results were comparable across subgroups (renal impairment, HRCA, elderly: ORR/≥VGPR 81.9%/58.3%, 84.7%/67.2%, 88.1%/65.3%; 12-mo PFS 45.5%, 55.6%, 53.0%; 12-mo OS 70.8%, 75.8%, 70.2%). Incidence of all-grade CRS was 47.9% (17.7% Gr2, 2.2% Gr3-4) in the overall cohort; incidence of all-grade ICANS was 6.1% (0.4% Gr≥3). The incidence and severity of CRS and ICANS did not differ substantially across subgroups. In the overall cohort, 9.0% of patients experienced at least one severe (Gr3-4) infection, compared to 6.9%, 8.2%, and 11.4% in the renal impairment, HRCA, and elderly subgroups. Across groups, most severe infections occurred within 6 months of talquetamab initiation. There were 2 infection-related deaths in the overall cohort. GPRC5D-related events were observed among 46.8% (oral), 46.5% (skin), and 36.8% (nail) of patients in the overall cohort, with similar rates across subgroups.  

Summary/Conclusion: In this cohort of real-world talquetamab patients in the US and EMEA, real-world effectiveness and safety outcomes were consistent with the pivotal MonumenTAL-1 trial, supporting the clinical value of talquetamab as a standard of care in the late-line RRMM across a range of treatment contexts and regardless of disease biology.

Johannes Waldschmidt, MD: Abbvie - Honoraria; Novartis - Honoraria; Sanofi-Aventis - Honoraria; GSK - Honoraria; Menarini-Stemline - Honoraria; Janssen - Honoraria; Oncopeptides - Honoraria; Bristol-Myers Squibb - Honoraria; Pfizer - Honoraria; Menarini-Stemline - Research Funding; Menarini-Stemline - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Oncopeptides - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Sanofi-Aventis - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony)